View AMCP comments to the CMS’s Draft CY 2026 Part D Redesign Program Instructions.
View AMCP comments to the CMS’s Advance Notice of Methodological Changes for Calendar Year (CY) 2026 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies
View AMCP comments to the FDA on considerations in demonstrating biosimilar interchangeability with a biologic reference product.
The Academy of Managed Care Pharmacy (AMCP) supports an abbreviated licensure pathway for the approval of biosimilar biologic drug therapies.
AMCP CEO Blog: AMCP’s roughly 8,000 members work diligently every day to improve patient care through the optimized use of medicines. As an organization, we also take a leading role in developing improvements to the overall delivery of care, which is no easy task given the size and complexity of our health care system.
Managed care pharmacy and prescription drug coverage is a growing part of the American health care sector. AMCP launched the annual Access, Affordability, and Outcomes report to raise awareness of the existence, prevalence, and importance of managed care pharmacy.
Press Release: AMCP Urges FDA to Issue Final Guidance on Biosimilar Interchangeability Standards and Provide Education on Substituting Interchangeable Products
Stakeholder letter expressing support for the Biosimilars Competition Act of 2018.
AMCP CEO Blog: The White House made news last month with its blueprint to lower drug prices. But it's also important to note that biosimilars will play a crucial role in fostering competition and lowering costs.
AMCP comment letter on New Hampshire legislation on medication synhcronization.
AMCP comment letter on state legislation on medication synchronization.
AMCP comment letter on state legislation on biological products dispensed by pharmacists.
